Kindred Biosciences (KIN) Misses Q4 EPS by 2c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• S&P 500 may pull back before midterms, but Citi says buy the dip